Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis

Gastroenterology

Volumn 142, Issue 3, 2012, Pages 442-452.e5

  Liao, Linda M ^a   Vaughan, Thomas L ^b   Corley, Douglas A ^c   Cook, Michael B ^a   Casson, Alan G ^d   Kamangar, Farin ^a,e   Abnet, Christian C ^a   Risch, Harvey A ^f   Giffen, Carol ^g   Freedman, Neal D ^a   Chow, Wongho ^a   Sadeghi, Shahram ^h   Pandeya, Nirmala ^h   Whiteman, David C ^h   Murray, Liam J ⁱ   Bernstein, Leslie ^j   Gammon, Marilie D ^k   Wu, Anna H ^l  

^a NATIONAL CANCER INSTITUTE   (United States)

^b USA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e MORGAN STATE UNIVERSITY   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INFORMATION MANAGEMENT SERVICES INC   (United States)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^k University of North Carolina at Chapel Hill   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Anti Inflammatory Agent; BEACON; Esophageal Neoplasm; Stomach Cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RISK FACTOR;

EID: 84857639909     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.11.019     Document Type: Article

References (45)

1. J. Steevens, A.A. Botterweck, M.J. Dirx Trends in incidence of oesophageal and stomach cancer subtypes in Europe Eur J Gastroenterol Hepatol 22 2010 669 678
2. M.B. Cook, W.H. Chow, S.S. Devesa Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005 Br J Cancer 101 2009 855 859
3. A. Jemal, R. Siegel, E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
4. S.S. Devesa, W.J. Blot, J.F. Fraumeni Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 1998 2049 2053
5. D.A. Corley, A. Kubo Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas J Natl Cancer Inst 96 2004 1383 1387
6. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 1971 232 235
7. B.J. Whittle, G.A. Higgs, K.E. Eakins Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa Nature 284 1980 271 273
8. C.D. Morris, G.R. Armstrong, G. Bigley Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence Am J Gastroenterol 96 2001 990 996
9. K.T. Wilson, S. Fu, K.S. Ramanujam Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res 58 1998 2929 2934
10. N.S. Buttar, K.K. Wang, M.A. Anderson The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study J Natl Cancer Inst 94 2002 422 429
11. R.A. Gupta, R.N. DuBois Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus J Natl Cancer Inst 94 2002 406 407
12. M. Baguma-Nibasheka, C. Barclay, A.W. Li Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma Mol Carcinog 46 2007 971 980
13. H.Y. Lim, H.J. Joo, J.H. Choi Increased expression of cyclooxygenase-2 protein in human gastric carcinoma Clin Cancer Res 6 2000 519 525
14. S.J. Cho, N. Kim, J.S. Kim The anti-cancer effect of COX-2 inhibitors on gastric cancer cells Dig Dis Sci 52 2007 1713 1721
15. X.H. Jiang, B.C. Wong Cyclooxygenase-2 inhibition and gastric cancer Curr Pharm Des 9 2003 2281 2288
16. M.V. Grau, J.R. Rees, J.A. Baron Chemoprevention in gastrointestinal cancers: current status Basic Clin Pharmacol Toxicol 98 2006 281 287
17. J.A. Baron, R.S. Sandler Nonsteroidal anti-inflammatory drugs and cancer prevention Annu Rev Med 51 2000 511 523
18. S. Ranka, J.M. Gee, I.T. Johnson Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer A case-control study Digestion 74 2006 109 115
19. T.L. Vaughan, L.M. Dong, P.L. Blount Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol 6 2005 945 952
20. L.A. Anderson, B.T. Johnston, R.G. Watson Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence Cancer Res 66 2006 4975 4982
21. J. Fortuny, C.C. Johnson, K. Bohlke Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers Clin Gastroenterol Hepatol 5 2007 1154 1159.e3
22. M. Lindblad, J. Lagergren, L.A. Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 14 2005 444 450
23. K. Akre, A.M. Ekstrom, L.B. Signorello Aspirin and risk for gastric cancer: a population-based case-control study in Sweden Br J Cancer 84 2001 965 968
24. D.C. Farrow, T.L. Vaughan, P.D. Hansten Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 7 1998 97 102
25. M.D. Gammon, M.B. Terry, N. Arber Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study Cancer Epidemiol Biomarkers Prev 13 2004 34 39
26. M. Epplein, A.M. Nomura, L.R. Wilkens Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study Am J Epidemiol 170 2009 507 514
27. D.A. Corley, K. Kerlikowske, R. Verma Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology 124 2003 47 56
28. W.H. Wang, J.Q. Huang, G.F. Zheng Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis J Natl Cancer Inst 95 2003 1784 1791
29. C.C. Abnet, N.D. Freedman, F. Kamangar Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis Br J Cancer 100 2009 551 557
30. C. Bosetti, S. Gallus, C. La Vecchia Aspirin and cancer risk: a summary review to 2007 Recent Results Cancer Res 181 2009 231 251
31. W. Tian, Y. Zhao, S. Liu Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer Eur J Cancer Prev 19 2010 288 298
32. M.B. Cook, F. Kamangar, D.C. Whiteman Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium J Natl Cancer Inst 102 2010 1 10
33. S. Sadeghi, C.J. Bain, N. Pandeya Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus Cancer Epidemiol Biomarkers Prev 17 2008 1169 1178
34. P.J. Veugelers, G.A. Porter, D.L. Guernsey Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma Dis Esophagus 19 2006 321 328
35. L. Duan, A.H. Wu, J. Sullivan-Halley Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County Cancer Epidemiol Biomarkers Prev 17 2008 126 134
36. N.D. Freedman, L.J. Murray, F. Kamangar Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium Gut 60 2011 1029 1037
37. J.P. Higgins, S.G. Thompson, J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
38. D.M. Nguyen, H.B. El-Serag, L. Henderson Medication usage and the risk of neoplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 7 2009 1299 1304
39. P. Tsibouris, M.T. Hendrickse, P.E. Isaacs Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma Aliment Pharmacol Ther 20 2004 645 655
40. D.M. Nguyen, P. Richardson, H.B. El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus Gastroenterology 138 2010 2260 2266
41. P.M. Rothwell, F.G. Fowkes, J.F. Belch Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
42. E.I. Heath, M.I. Canto, S. Piantadosi Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial J Natl Cancer Inst 99 2007 545 557
43. D. Das, S. Ishaq, R. Harrison Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial Am J Gastroenterol 103 2008 1079 1089
44. S.S. Husain, I.L. Szabo, A.S. Tamawski NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action Am J Gastroenterol 97 2002 542 553
45. M.J. Thun, S.J. Henley, C. Patrono Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues J Natl Cancer Inst 94 2002 252 266